Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer

BACKGROUND: The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival (OS) in bladder cancer patients in the BCON phase III clinical trial. We investigate whether expression of hsa-miR-210 in BCON patient samples reflects hypoxia and predicts be...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Cancer
Главные авторы: Irlam-Jones, J J, Eustace, A, Denley, H, Choudhury, A, Harris, A L, Hoskin, P J, West, C M L
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2016
Предметы:
Molecular Diagnostics
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4997544/
https://ncbi.nlm.nih.gov/pubmed/27441495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.218
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы